Bladou F, Thuret R, Gravis G, Karsenty G, Serment G, Salem N
Service d'urologie, hôpital Salvator, 249, boulevard de Sainte-Marguerite, BP51, 13274 Marseille, France.
Ann Urol (Paris). 2007 Apr;41(2):68-79. doi: 10.1016/j.anuro.2007.02.001.
Permanent seed brachytherapy as a monotherapy is an appropriate treatment in patients with low risk localized prostate cancer such as intraprostatic cancer, T1-2 stage, PSA less than 10 ng/mL, low tumour volume, well differentiated cancer (Gleason score less than 7), gland size less than 50 mL, no micturition symptoms that could decompensate after implantation. A brachytherapy program needs a specialized multidisciplinary team with the collaboration of urologists, radiotherapists (authorized person to manipulate radioactive elements), and physicists. The 10-year oncologic and morbidity results have been published in the literature and are comparable to those of other standard treatments of localized prostate cancer such as radical prostatectomy and external beam radiation therapy.
永久性粒子植入近距离放射治疗作为单一疗法，适用于低风险局限性前列腺癌患者，如前列腺内癌、T1-2期、前列腺特异性抗原（PSA）低于10 ng/mL、肿瘤体积小、高分化癌（ Gleason评分低于7分）、腺体大小小于50 mL、植入后不会出现失代偿性排尿症状的患者。近距离放射治疗方案需要一个专业的多学科团队，由泌尿科医生、放射治疗师（有权操作放射性元素的人员）和物理学家协作。10年的肿瘤学和发病率结果已在文献中发表，与局限性前列腺癌的其他标准治疗方法（如根治性前列腺切除术和外照射放疗）相当。
